Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a biopharmaceutical company that discovers, develops, and commercializes therapeutic medicines for patients facing rare diseases, particularly conditions with limited treatment options. The company focuses its portfolio across therapeutic areas addressing rare sleep disorders, rare epilepsies, and rare oncology. Key commercial products include Xywav and Xyrem for sleep disorders such as narcolepsy and idiopathic hypersomnia; Epidiolex for severe childhood-onset seizure syndromes including Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex; and oncology therapies such as Ziihera, Modeyso, Zepzelca, and Rylaze for diverse cancers. Its customers comprise adult and pediatric patients diagnosed with these targeted conditions.

The company maintains an international commercial footprint, marketing approved therapies to patients across multiple global regions. Key international territories and markets explicitly served include the United States, Canada, the European Union, Great Britain, Switzerland, Australia, and Israel, with its rare epilepsy medicine launched and reimbursed in more than 40 countries. In the United States, its primary sleep disorder medicines are distributed directly to individuals through an exclusive central pharmacy. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Jazz Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, Jazz employed approximately 2,890 people worldwide, with approximately 53% in the U.S.”